Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
International Journal of Paleopathology|May 21, 2018
A case of benign osteogenic tumour in Homo naledi: Evidence for peripheral osteoma in the U.W. 101-1142 mandibleEdward J Odes, Lucas K Delezene, Patrick S Randolph-Quinney, et al.
Facial Plastic Surgery Clinics of North America|March 22, 2008
Roundtable: discussion of "the difficult patient"Bruce F Connell, Jack Gunter, Toby Mayer, et al.
British Journal of Cancer|May 26, 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)G K Schwartz, P M LoRusso, M A Dickson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2008
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphomaM Crump, B Coiffier, E D Jacobsen, et al.
Current Medical Research and Opinion|February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatmentT Bell, J P Crown, I Lang, et al.
Journal of Molecular Biology|May 30, 2020
Out-of-Register Parallel β-Sheets and Antiparallel β-Sheets Coexist in 150-kDa Oligomers Formed by Amyloid-β(1-42)Yuan Gao, Cong Guo, Jens O Watzlawik, et al.
Scientific Reports|October 14, 2015
Evidence of fatal skeletal injuries on Malapa Hominins 1 and 2Ericka N L'Abbé, Steven A Symes, James T Pokines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Facial Plastic Surgery Clinics of North America|October 27, 2010
Office managers' forumSamuel M Lam, Launa Hankins, Andrea Dieter, et al.
Haematologica|April 10, 2025
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 studyTae Min Kim, Nehal J Lakhani, Jacob Soumerai, et al.
Pageof 5